Phase 2
Completed N=89
Safety, Pharmacokinetics, and Efficacy of Bepotastine Besilate Nasal Product After Ragweed Pollen Exposure in an Environmental Chamber
Source: ClinicalTrials.gov NCT01222299 ↗Enrolled (actual)
89
Serious AEs
0.0%
Results posted
Sep 2020
Primary outcomePrimary: Mean Change From Baseline (Pre-Dose) in Subject-rated Instantaneous TNSS — -1.17; -0.69; -2.43; -1.65 units on a scale
Summary
The purpose of this study is to examine the safety and efficacy of bepotastine besilate nasal product in seasonal allergic rhinitis patients.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Mean Change From Baseline (Pre-Dose) in Subject-rated Instantaneous TNSS |
-1.17; -0.69; -2.43; -1.65; -1.63; -0.64 | — |
Eligibility Criteria
Inclusion Criteria
- Subjects 18 to 65 years of age with a positive skin prick test with ragweed allergen
Exclusion Criteria
- No active respiratory tract infection
Data sourced from ClinicalTrials.gov (NCT01222299). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.